Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines - PubMed (original) (raw)
. 1995 Oct 15;55(20):4633-9.
Affiliations
- PMID: 7553641
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines
N Borsellino et al. Cancer Res. 1995.
Abstract
Hormonal treatment of advanced prostatic cancer patients generally results in an initially beneficial response, but the treated patients develop hormonally resistant disease in which no curative therapy is currently available. Recent studies have revealed that interleukin 6 (IL-6) is a growth factor for myeloma, renal cell carcinoma, and certain T-cell lymphomas. Further, IL-6 has been shown to block apoptosis induced by p53, transforming growth factor beta, and certain cancer chemotherapeutic compounds. The objective of the present study was to determine whether IL-6 is a growth factor for two human prostate cancer lines and whether it protects the tumor cells from drug-induced cell death. Two hormone-independent prostate cell lines were used in this study, namely PC-3 and DU145, and these have been shown to be relatively resistant to cis-diamminedichloroplatinum (CDDP), etoposide (VP-16), and adriamycin (ADR). Both cell lines express IL-6 mRNA and secrete IL-6 constitutively. The addition of anti-IL-6 antiserum to the cell lines resulted in a significant inhibition of cell growth up to day 2, and when additional antibody was added at day 2 the inhibition persisted for 4 days. The coaddition of anti-IL-6 antiserum and CDDP or VP-16 resulted in synergy in cytotoxicity in both cell lines, whereas the combination of antibody and ADR or suramin resulted only in additive effects. Sequential treatment revealed that anti-IL-6 antibody was required to achieve synergy, whereas either sequence of pretreatment resulted in synergy with anti-IL-6 and CDDP but not with VP-16. CDDP treatment of tumor cells down-regulated IL-6 mRNA expression and IL-6 secretion. The present findings demonstrate that IL-6 is an autocrine/paracrine growth factor for DU145 and PC-3 prostate lines. Additionally, the secretion of this cytokine protects the tumor cells against the cytotoxic effect of CDDP and VP-16 and its neutralization sensitizes the cells to cytotoxicity. Overall, the studies suggest that agents that can down-regulate or inhibit protective factors in tumors may overcome drug resistance.
Similar articles
- Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Uslu R, et al. Clin Cancer Res. 1997 Jun;3(6):963-72. Clin Cancer Res. 1997. PMID: 9815772 - Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y, Yoshida O, Bonavida B. Mizutani Y, et al. J Urol. 1998 Aug;160(2):561-70. J Urol. 1998. PMID: 9679929 - The evidence for interleukin-6 as an autocrine growth factor in malignancy.
Akira S, Kishimoto T. Akira S, et al. Semin Cancer Biol. 1992 Feb;3(1):17-26. Semin Cancer Biol. 1992. PMID: 1643291 Review. - Interleukin 6 and cancer treatment.
Martínez-Maza O, Berek JS. Martínez-Maza O, et al. In Vivo. 1991 Nov-Dec;5(6):583-8. In Vivo. 1991. PMID: 1810443 Review.
Cited by
- SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growth.
Park SY, Na Y, Lee MH, Seo JS, Lee YH, Choi KC, Choi HK, Yoon HG. Park SY, et al. Oncotarget. 2016 Jul 5;7(27):41110-41122. doi: 10.18632/oncotarget.9002. Oncotarget. 2016. PMID: 27129164 Free PMC article. - Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor.
Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Lu Y, et al. Clin Exp Metastasis. 2004;21(5):399-408. doi: 10.1007/s10585-005-0056-6. Clin Exp Metastasis. 2004. PMID: 15672864 - Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.
Culig Z. Culig Z. Am J Clin Exp Urol. 2014 Oct 2;2(3):231-8. eCollection 2014. Am J Clin Exp Urol. 2014. PMID: 25374925 Free PMC article. Review. - IL-6 gene amplification and expression in human glioblastomas.
Tchirkov A, Rolhion C, Bertrand S, Doré JF, Dubost JJ, Verrelle P. Tchirkov A, et al. Br J Cancer. 2001 Aug 17;85(4):518-22. doi: 10.1054/bjoc.2001.1942. Br J Cancer. 2001. PMID: 11506489 Free PMC article. - Natriuretic peptide receptor a as a novel target for prostate cancer.
Wang X, Raulji P, Mohapatra SS, Patel R, Hellermann G, Kong X, Vera PL, Meyer-Siegler KL, Coppola D, Mohapatra S. Wang X, et al. Mol Cancer. 2011 May 17;10:56. doi: 10.1186/1476-4598-10-56. Mol Cancer. 2011. PMID: 21586128 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous